Physician profile
Brian A Foley
NPI 1871539593
$8,927.25
in general payments reported to CMS, 2019-2025
33 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $387 · 2021: $748 · 2022: $1,190 · 2023: $477 · 2024: $4,149 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,225 · Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,224.81 |
| Food and Beverage | $2,928.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,966.72 | 2019-2025 | Emblem Mri S-Icd, S-Icd System Magnet, Watchman Access System |
| Merck Sharp & Dohme LLC | $956.20 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $684.60 | 2024 | |
| Novartis Pharmaceuticals Corporation | $658.37 | 2019-2025 | |
| Esperion Therapeutics, INC. | $371.30 | 2020-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $152.59 | 2019-2024 | Opsumit |
| Amgen INC. | $151.71 | 2020-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $128.91 | 2020-2021 | |
| Elutia, INC. | $98.59 | 2019-2025 | Ecm Patch,Pouch |
| Regeneron Healthcare Solutions, INC. | $87.16 | 2019 | |
| Novo Nordisk INC | $81.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.98 | 2019-2023 | Jardiance |
| Cvrx, INC. | $65.67 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $65.41 | 2023-2024 | Inpefa |
| Philips North America LLC | $44.58 | 2020-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $39.51 | 2024 | |
| Pfizer INC. | $38.81 | 2019 | |
| Inspire Medical Systems, INC. | $38.05 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $34.91 | 2024 | Eliquis, Camzyos |
| Biosense Webster, INC. | $33.48 | 2024 | Carto 3 |
| Kowa Pharmaceuticals America, INC. | $26.71 | 2020-2021 | |
| Lantheus Medical Imaging, INC. | $25.56 | 2021 | |
| United Therapeutics Corporation | $21.52 | 2022 | |
| Irhythm Technologies, INC. | $17.74 | 2019 | |
| Medtronic, INC. | $16.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.15 | 2024 | |
| Baxter Healthcare | $13.26 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Gilead Sciences, INC. | $11.92 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.